Yazar "Ozturk, P." seçeneğine göre listele
Listeleniyor 1 - 20 / 31
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Anesthetic Management for Left Ventricular Assist Device Implantation Through Left Thoracotomy: Evaluation of On-Pump Versus Off-Pump(Elsevier Science Inc, 2017) Sahutoglu, C.; Turksal, E.; Bilic, U.; Kocabas, S.; Askar, F. Zekiye; Ozturk, P.; Ertugay, S.; Engin, C.; Yagdi, T.; Ozbaran, M.Background. Ventricular assist devices (VADs) are alternative approaches to medical treatment in patients with acute or chronic heart failure. The goal of this study was to compare an anesthetic approach in patients undergoing implantation of a VAD with (on pump) or without (off-pump) cardiopulmonary bypass (CPB) through left thoracotomy. Methods. A total of 32 patients were divided into 2 groups: on-pump (group 1) and off pump (group 2). A standard anesthesia protocol was used in all patients. Baseline characteristics of the patients, intraoperative hemodynamic and respiratory variables, anesthetic agents and vasoactive drugs administered, the amount of blood products, extubation, length of hospital stay and intensive care unit stay, and postoperative complications were recorded. Results. Patients' mean age was 54.7 +/- 13.3 years (range, 18-74 years). Eighteen patients underwent surgery with CPB. Demographic data of the patients, preoperative characteristics, intraoperative use of blood products, intraoperative complications, and anesthetic drugs used were similar between groups (P >.05). The duration of surgery (219 +/- 23 vs 273 +/- 56 minutes) and anesthesia (274 +/- 38 vs 323 +/- 57 minutes) were shorter in group 2; there was no difference between the 2 groups in terms of mechanical ventilation time, length of stay in the intensive care unit, and length of hospital stay. There was no decrease in postoperative oxygen parameters and an increase in patient lactate levels with the use of CPB. The use of fresh frozen plasma and platelet suspension in the postoperative period was significantly higher in group 1 (P <.05). The rate of complications and mortality rate were comparable between the 2 groups (P >.05). Conclusions. Our study results show that the use of CPB during VAD implantation via left thoracotomy increases operation time and use of blood products, while causing no change in the rate of complications.Öğe The Association Between the Low Percentage of Forced Vital Capacity and Increased Mortality After LVAD Operation(Amer Thoracic Soc, 2018) Ekren, P. Korkmaz; Ertugay, S.; Ozturk, P.; Ozdil, A.; Nalbantgil, S.; Engin, C.; Yagdi, T.; Ozbaran, M.Öğe Changes in plasma neprilysin levels after left ventricular assist device implantation and association of outcomes during 1-year follow-up(Wiley, 2019) Yuce, E. I. Elif Ilkay; Demir, E.; Simsek, E.; Ozturk, P.; Parildar, Z.; Engin, C.; Yagdi, T.; Ozbaran, M.; Nalbantgil, S.; Gurgun, C.Öğe Changes in plasma neprilysin levels after left ventricular assist device implantation and association with short-term outcomes(Oxford Univ Press, 2018) Yuce, E. I.; Demir, E.; Simsek, E.; Ozturk, P.; Parildar, Z.; Engin, C.; Yagdi, T.; Ozbaran, M.; Nalbantgil, S.; Gurgun, C.Öğe Coronary artery bypass surgery in three patients with haemophilia(Wiley, 2019) Sahin, F.; Atilla, F. D.; Demirci, Z.; Ozturk, P.; Ozbaran, M.Öğe Diagnosis and Management of Pump Thrombosis in Patients with Continuous-Flow Ventricular Assist Devices(Elsevier Science Inc, 2016) Ertugav, S.; Engin, C.; Daylan, A.; Pektok, E.; Ozturk, P.; Nalbantgil, S.; Yagdi, T.; Ozbaran, M.Öğe Effect of aortic valve opening pattern on endothelial functions after continuous flow left ventricular assist device implantation(Wiley, 2017) Kaya, E.; Simsek, E.; Nalbantgil, S.; Akilli, A.; Ozturk, P.; Engin, C.; Yagdi, T.; Ozbaran, M.Öğe Efficacy and Safety of Ferric Carboxymaltose Therapy in Continuous Flow LVAD Patients(Elsevier Science Inc, 2019) Demir, E.; Nalbantgil, S.; Ozturk, P.; Simsek, E.; Engin, C.; Yagdi, T.; Ozbaran, M.Öğe Evaluation of Functional Capacity Scores After Left Ventricular Assist Device Implantation in Cases with End Stage Heart Failure(Elsevier Science Inc, 2016) Ozturk, P.; Ertugay, S.; Nalbantgil, S.; Karapolat, H.; Engin, C.; Yagdi, T.; Ozbaran, M.Öğe Eye of Stranger: Evaluate of Chorioretinal Microvascular Networks on Ventricular Assist Device(Elsevier Science Inc, 2020) Ozturk, P.; Ozturk, T.; Demir, E.; Kahraman, U.; Engin, C.; Yagdi, T.; Ozbaran, M.[No abstract available]Öğe Frailty and Clinical Outcomes Following Left Ventricular Assist Device Implantation(Elsevier Science Inc, 2019) Uzun, H. G.; Demir, E.; Simsek, E.; Capanoglu, T.; Karapolat, H.; Engin, C.; Yagdi, T.; Ozturk, P.; Ozbaran, M.; Nalbantgil, S.Öğe Heartmate 3 versus Heartmate 2: Is New Always Better ?(Elsevier Science Inc, 2018) Ozturk, P.; Demir, E.; Sahutoglu, C.; Engin, C.; Yagdi, T.; Nalbantgil, S.; Ozbaran, M.Öğe HeartWare Continuous flow left ventricular assist device early mortality predictors: Single center experience(Wiley, 2017) Demir, E. Emre; Ozturk, P.; Engin, C. E.; Nalbantgil, S. N.; Zoghi, M. Z.; Yagdi, T. Y.; Ozbaran, M. O.Öğe Intracranial Hemorrage in Patients with Continous Flow LVAD(Elsevier Science Inc, 2019) Demir, E.; Nalbantgil, S.; Ozturk, P.; Simsek, E.; Engin, C.; Yagdi, T.; Ozbaran, M.Öğe Is there a heart rate paradox in heart transplantation?(Wiley-Blackwell, 2016) Kocabas, U. Umut; Kaya, E.; Ertugay, S.; Ozturk, P.; Engin, C.; Nalbantgil, S.; Zoghi, M.; Yagdi, T.; Ozbaran, M.Öğe Left Ventricular Assist Device Implantation by Lateral Thoracotomy to the Descending Aorta: A Propensity Matched Analysis to Standard Sternotomy Approach(Elsevier Science Inc, 2016) Ozbaran, M.; Yagdi, T.; Engin, C.; Nalbantgil, S.; Ertugay, S.; Ozturk, P.Öğe Left Ventricular Assist Device Implantation in Heart Failure Patients With a Left Ventricular Thrombus(Elsevier Science Inc, 2013) Engin, C.; Yagdi, T.; Balcioglu, O.; Erkul, S.; Baysal, B.; Oguz, E.; Ayik, F.; Ozturk, P.; Ozbaran, M.Background. In this report, we share our experience with left ventricular assist device (LVAD) implantation in cases with a left ventricular (LV) thrombus. Method. Over the 3 years, more than 100 end-stage heart failure cases have been treated with LVAD implantation in our center, including 6 patients with a LV thrombus. Three were detected using preoperative transthoracic echocardiography. Fifty percent of the patients had dilated cardiomyopathy and the remaining cases had an ischemic etiology. Double inotropic support with dopamine and dobutamine was used in all, with 3 drugs with the addition of adrenaline in 2 patients. In 4 cases we implanted the Heart Ware Ventricular Assist System (Heart Ware, Inc., Miramar, Fla, United States) and in the remaining 2 patients, the Berlin Heart EXCOR ventricular assist device (Berlin Heart AG, Berlin, Germany) for biventricular support. In 1 patient the apical ventriculotomy was extended to remove an intertrabecular thrombosis and ventricular septal surface covered with a dacron patch to minimize the thrombogenic potential. Results. Two patients died due to sepsis and multiorgan failure. None of the patients experienced a neurological event, pump thrombosis, or pump malfunction. Two subjects underwent re-explorations due to hemorrhage. Two candidates underwent successfull transplantation without any evidence of thrombosis in the explanted heart or device. Conclusion. We believe that patients with a LV thrombus and preserved right ventricular function are good candidates for implantation of a LVAD after removing the intracavitary thrombus.Öğe Long-term Results of Autologous Stem Cell Transplantation in the Treatment of Patients With Congestive Heart Failure(Elsevier Science Inc, 2011) Oguz, E.; Ayik, F.; Ozturk, P.; Engin, C.; Nalbantgil, S.; Yagdi, T.; Ozbaran, M.Background. The aim of this study was to assess the long-term efficacy of stem cell transplantation with revascularization for patients with ischemic cardiomyopathy. Methods. We enrolled 17 patients with ischemic cardiomyopathy who had undergone autologous stem cell treatment. To assess myocardial ischemia and viability they underwent coronary angiography, stress tests with dobutamine, echocardiography, and positron emission tomography. Peripheral stem cells mobilized using granulocyte colony-stimulating factor (G-CSF) were collected by aphseresis for transplantation transmyocardially into the areas of injury during coronary artery bypass surgery to increase blood flow to the engrafted areas. Results. Three patients died in the early follow-up period and 4 patients with cardiac failure died during mid-term follow-up; they all underwent stem cell transplantation at 6 months after acute myocardial infarction. The mean follow-up period of the remaining 10 patients was 85.8 +/- 9.2 months (range, 70-100). Mean left ventricular ejection fraction improved to 30.0 +/- 6.7, whereas the preoperative mean left ventricular ejection fraction of the surviving patients was 25.6 +/- 4.5 (P = .035). Mean New York Heart Association (NYHA) functional class decreased from 3.2 to 1.5 (P = .006). When the study population was divided into 2 subgroups according to the interval between acute myocardial infraction and surgery, the patients who underwent autologous stem cell transplantation within the first 6 months after myocardial infraction (Group 1) showed significantly lower NYHA scores at the last follow-up (P = .024 in Group 1 and P = .102 in Group 2). No side effects were observed to be due to the stem cell or G-CSF injections. Conclusion. Treatment of ischemic cardiomyopathy with autologous stem cell transplantation is easy and safe, opening a new window in the treatment of "no hope" patients.Öğe Outcomes of Low Dose Strategy of Thrombolytic Therapy for Pump Thrombosis(Elsevier Science Inc, 2017) Ertugay, S.; Ozturk, P.; Engin, C.; Demir, E.; Nalbantgil, S.; Yagdi, T.; Ozbaran, M.Öğe The outcomes of surgery for heart failure in paediatric patients: the experience of a University in Turkey(Wiley-Blackwell, 2015) Engin, C.; Ertugay, S.; Ulger, Z.; Ozturk, P.; Ayik, M. F.; Atay, Y.; Yagdi, T.; Ozbaran, M.
